Chong Kun Dang Pharmaceutical Cash Flow-to-Debt Ratio
Chong Kun Dang Pharmaceutical cash flow-to-debt ratio. Chong Kun Dang Pharmaceutical (185750) has a Cash Flow-to-Debt Ratio of 0.02x as of March 2026, meaning its operating cash flow of ₩12.32 Billion could theoretically repay 0% of its total liabilities (₩803.02 Billion) in one year. Check Chong Kun Dang Pharmaceutical cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Chong Kun Dang Pharmaceutical (2016–2025)
Cash flow-to-debt ratio of Chong Kun Dang Pharmaceutical from 2016 to 2025. Historical debt coverage capacity for Chong Kun Dang Pharmaceutical across 10 annual periods. Check 185750 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Chong Kun Dang Pharmaceutical Cash Flow-to-Debt Ratio by Year (2016–2025)
Chong Kun Dang Pharmaceutical cash flow-to-debt ratio by year from 2016 to 2025. Year-by-year debt coverage analysis for Chong Kun Dang Pharmaceutical. For the full cash flow conversion analysis, see Chong Kun Dang Pharmaceutical (185750) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.08x | ₩67.36 Billion | ₩793.94 Billion | ▼ -25.8% |
| 2024 | 0.11x | ₩64.29 Billion | ₩562.39 Billion | ▼ -78.9% |
| 2023 | 0.54x | ₩318.16 Billion | ₩586.79 Billion | ▲ +303.1% |
| 2022 | 0.13x | ₩67.73 Billion | ₩503.59 Billion | ▲ +401.3% |
| 2021 | 0.03x | ₩12.90 Billion | ₩480.89 Billion | ▼ -89.8% |
| 2020 | 0.26x | ₩104.32 Billion | ₩394.74 Billion | ▲ +11.6% |
| 2019 | 0.24x | ₩77.29 Billion | ₩326.40 Billion | ▲ +55.9% |
| 2018 | 0.15x | ₩42.63 Billion | ₩280.60 Billion | ▼ -49.1% |
| 2017 | 0.30x | ₩81.67 Billion | ₩273.91 Billion | ▲ +48.3% |
| 2016 | 0.20x | ₩57.79 Billion | ₩287.45 Billion | — |